Cost-effectiveness and drug wastage of immunotherapeutic agents for hematologic malignancies: a systematic review-Reference-Cited by-同舟云学术

Cost-effectiveness and drug wastage of immunotherapeutic agents for hematologic malignancies: a systematic review

Published:2021-05-02 Issue:5 Volume:21 Page:923-941
ISSN:1473-7167
Container-title:Expert Review of Pharmacoeconomics & Outcomes Research
language:en
Short-container-title:Expert Review of Pharmacoeconomics & Outcomes Research

Author:

Chen Ziyan¹,Cheng Yue²,DeRemer David³,Diaby Vakaramoko¹^ORCID

Affiliation:

1. Department of Pharmaceutical Outcomes & Policy (POP), College of Pharmacy, University of Florida, Gainesville, Florida, United States

2. Institute for Pharmaceutical Outcomes & Policy (IPOP), Department of Pharmacy Practice and Science, College of Pharmacy, University of Kentucky, Lexington, Kentucky, United States

3. Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, Florida, United States

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Health Policy,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737167.2021.1913056

Reference75 articles.

1. Immunotherapy in hematologic malignancies: past, present, and future

2. Rituximab for Non-Hodgkin's Lymphoma: A Story of Rapid Success in Translation

3. Follicular lymphoma: evolving therapeutic strategies

4. Haematological malignancies: at the forefront of immunotherapeutic innovation

5. Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Engineered bacteria in tumor immunotherapy;Cancer Letters;2024-05